Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 40Anemia, Refractory, with Excess of Blasts 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Leukemia, Lymphocytic, Chronic, B-Cell 28Myelodysplastic Syndromes 27Lymphoma, Non-Hodgkin 27Leukemia, Myelomonocytic, Chronic 27Hodgkin Disease 27Multiple Myeloma 24Primary Myelofibrosis 21Myeloproliferative Disorders 21Lymphoma, Follicular 21Leukemia 21Lymphoma 20Lymphoma, Mantle-Cell 19Congenital Abnormalities 19Leukemia, Myeloid, Chronic-Phase 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Anemia, Refractory 18Lymphoma, B-Cell, Marginal Zone 17Burkitt Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Large-Cell, Immunoblastic 15Leukemia, Myeloid, Accelerated Phase 15Dendritic Cell Sarcoma, Interdigitating 13Neoplasms, Plasma Cell 12Recurrence 11Blast Crisis 11Anemia, Aplastic 11Leukemia, Myelomonocytic, Juvenile 10

Interventions

Cyclophosphamide 3thymoglobulin 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Mycophenolic Acid × Classical hematology × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡